Newborn screening for cystic fibrosis

Area of Science:

• Medical Genetics
• Neonatal Screening
• Public Health

Background:

• The immunoreactive trypsinogen assay was recognized in the late 1970s for early cystic fibrosis identification in infants.
• Newborn blood spot screening (NBS) for cystic fibrosis has been continuously evaluated and expanded since its inception.
• NBS for cystic fibrosis is a cost-effective strategy with positive clinical outcomes when care standards and management pathways are robustly implemented.

Purpose of the Study:

• To review the evolution and current status of newborn blood spot screening for cystic fibrosis.
• To highlight the benefits of early diagnosis and care access for infants with cystic fibrosis.
• To identify future research directions for optimizing cystic fibrosis NBS programs.

Main Methods:

• Review of historical data and performance assessments of cystic fibrosis NBS programs.
• Analysis of the expansion and impact of NBS over the past decade.
• Discussion of current trends and future research needs in cystic fibrosis screening.

Main Results:

• Newborn blood spot screening for cystic fibrosis has undergone rapid expansion, increasing early diagnosis and care access for infants.
• The screening strategy is cost-effective and improves clinical outcomes when implemented with high standards of care.
• Cystic fibrosis NBS is transitioning from development to an era of consolidation.

Conclusions:

• Cystic fibrosis NBS is a mature and effective public health strategy.
• Future research should focus on program rationalization, optimization, and addressing bioethical implications.
• Ethical considerations include managing incidental findings like carrier detection and inconclusive diagnoses.